Back to Search Start Over

Switching to aromatase inhibitor Arimidex cuts breast cancer relapse 40%

Source :
Pharma Marketletter. August 15, 2005
Publication Year :
2005

Abstract

Switching postmenopausal women with endocrine-responsive early breast cancer to the aromatase inhibitor anastrozole (AstraZeneca's Arimidex) after two years' adjuvant tamoxifen treatment results in a 40% reduction in the risk of [...]

Subjects

Subjects :
Arimidex (Medication) -- Research
Care and treatment
Research
Anastrozole -- Research
Aromatase inhibitors -- Research
Breast cancer -- Care and treatment -- Research

Details

Language :
English
ISSN :
13558501
Database :
Gale General OneFile
Journal :
Pharma Marketletter
Publication Type :
News
Accession number :
edsgcl.135179402

Tools

Authors Abstract Subjects Details